New hope for hard-to-treat hepatitis c: experimental combo shows promise
NCT ID NCT00781274
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called MP-424 combined with two standard medications (peginterferon alfa-2b and ribavirin) in 32 adults with genotype 1 hepatitis C who had not responded to earlier treatment. The main goal was to see if the virus could be cleared from the blood 24 weeks after treatment ended. The study is complete, and results help guide future treatment options for this difficult-to-treat group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C GENOTYPE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Toranomon Hospital
Kawasaki, Takatsu-ku, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A Finger-Prick could change the fight against hepatitis c
- A simple finger prick could transform hepatitis c care
- Can coaching clinics curb HIV? a new strategy puts it to the test
- Can hepatitis c be cured in just 4 weeks? a new trial puts it to the test
- Can a simple roadside test catch liver disease before it turns deadly?
- Pharmacy-Based hepatitis c testing could cure more people on opioid therapy